Why Is RADL3 Falling Today?
RADL3 (Raia Drogasil) dropped 7.02% on September 24, 2026, closing at R$ 18.13 compared to R$ 19.50 the previous day. During the same trading session, the Ibovespa fell just 0.94%, and the median stock on the exchange actually rose (+1.09%). There was no material fact released by the company: the decline stemmed entirely from the pharmacy sector, pressured by a cascade of generic GLP-1 weight-loss pen approvals granted by ANVISA in recent weeks.
Data compiled as of 7:02 PM on September 24, 2026. Raia Drogasil's documents at CVM were checked, and no material facts were found dated September 24, 2026. The decline, therefore, did not stem from an announcement by the company itself—it reflects how the market interpreted the sector as a whole. Nor was it a low-liquidity flash move: nearly 30% of the day's turnover (R$ 46.2 million) changed hands directly at the lower price level, signaling a genuine move backed by real capital.
What Is RADL3, for Those Just Tuning In
RADL3 is the ticker symbol for the shares of Raia Drogasil, Brazil's largest pharmacy chain, formed by the merger of Droga Raia and Drogasil. The company operates roughly 2,900 stores across the country, selling medications alongside hygiene, beauty, and convenience items.
A substantial portion of a pharmacy's margin does not come from soap or cheap generics—it comes from high-value medications, the kind where customers spend R$ 300, R$ 500, or more at the register. In recent years, no category has grown faster at the pharmacy counter than weight-loss pens. Consequently, any shift in the pricing of these drugs directly impacts the profit thesis for these companies.
The "Pen Effect": ANVISA's Cascade of Approvals
The so-called weight-loss pens are medications belonging to the GLP-1 class. The two most well-known names to the public are semaglutide (sold as Ozempic and Wegovy) and liraglutide (sold as Victoza and Saxenda). Until recently, these drugs were protected by patents and sold at very high prices, securing a fat average ticket per unit for pharmacies.
What changed was a rapid sequence of regulatory approvals. In a little over a month, Brazil shifted from an environment dominated almost entirely by original brand-name drugs to a market on the verge of being flooded with lower-priced alternatives:
| Date | What ANVISA Approved | Source |
|---|---|---|
| 08/17/2026 | First generic semaglutide (EMS) | CNN Brasil, Correio Braziliense, Agência Brasil |
| 08/24/2026 | Second generic semaglutide (Germed) | Diário Oficial da União |
| Apr 9, 2026 | Semavy (synthetic semaglutide pen) hits pharmacies at R$ 333–464 | Reported in pharmaceutical retail |
| Aug 9, 2026 | First two generic liraglutide versions (EMS) | Olhar Digital, SpaceMoney |
| 09/14/2026 | 14 additional diabetes/obesity pens approved | Portal 6 |
The financial logic behind the selloff is straightforward. Generics enter the market priced between 35% and 65% of the reference price of the brand-name drug. For consumers, this is excellent news. For pharmacies, it creates two simultaneous pressures: average ticket prices fall (the same box is worth much less) and margins compress (the product has become a commodity, and commodities sell on price).
The severity of the hit varies by chain, but one figure helps put it in perspective: GLP-1 drugs accounted for up to 8.2% of Pague Menos' sales and represent a relevant share of Raia Drogasil's own revenue. When a category of this weight loses value from one month to the next, the market anticipates the earnings impact and sells off the stock before the results appear in financial statements.
The Company's Drop Is Not a Market Drop
This is the distinction that separates panic from analysis. September 24, 2026, was not a bad day for the stock exchange. The Ibovespa fell just 0.94%, and the median stock in the trading session gained 1.09%, meaning most equities closed in positive territory. If RADL3's 7% drop were the market's fault, it would have been accompanied by a broad market downturn. That was not the case.
Instead, what occurred was a coordinated selloff concentrated in pharmacies and retail, stock by stock:
| Ticker | Company | Return on 09/24 |
|---|---|---|
| PGMN3 | Pague Menos | -8.56% |
| SBFG3 | Grupo SBF (Centauro) | -8.53% |
| PNVL3 | Panvel | -8.26% |
| RADL3 | Raia Drogasil | -7.02% |
| VIVA3 | Vivara | -4.53% |
| RAIZ4 | Raízen (other sector) | +3.57% |
Notice the contrast. The other three exchange-listed pharmacy chains dropped even further than RADL3. Meanwhile, RAIZ4, which operates in a different sector (energy/fuels), rose 3.57% on the same day. This is the hallmark of a sector-specific and selective movement rather than general market gloom: capital exited specifically from companies reliant on pharmacy counters and domestic retail, rather than the broader stock market.
What this means in practice: if you are a RADL3 shareholder who opened your brokerage account today in a panic, the explanation does not lie in your individual stock—it stems from a thesis the market has begun applying to the entire pharmacy sector. Understanding this changes the right question to ask: it is not "what did Raia do wrong?", but rather "how much of pharmacies' profits came from expensive pens, and how much of that will generics wash away?"
Other Headwinds That Were Already Weighing In
The "pen effect" served as the immediate catalyst, but it landed on a sector that was already fragile. Three factors help explain why the reaction was so sharp:
- CMED's 2026 price adjustment of 3.81%. The Chamber of Regulation of the Medicine Market sets the ceiling for annual drug price adjustments. This year's index came in below the cost inflation pharmacy chains face (source: Monitor Mercantil), which was already squeezing margins even before the generics story emerged.
- The stock was already declining. RADL3 is down 28% to 36% year-to-date in 2026. In other words, the market was already skeptical, and today's session reinforced a trend that did not start yesterday.
- High Selic rates punish stretched multiples. With elevated interest rates, investors demand a higher return to pay up for future earnings. RADL3 trades at a price-to-earnings (P/E) multiple of around 26x—a high multiple that leaves it especially vulnerable whenever a threat to earnings growth arises.
It is worth noting that some equity research desks pointed in the opposite direction of the panic: in earlier assessments, XP and Bradesco BBI stated that the market was "over-pricing" GLP-1 risk. This is an analytical claim by research firms rather than a settled fact, but it demonstrates that the very risk that dragged down the stock today is far from reaching a consensus.
What to Monitor Going Forward
Without price forecasts or investment recommendations, what remains to be monitored are the facts that will determine whether the margin compression thesis is confirmed or if the market overreacted:
- New GLP-1 generics. ANVISA has signaled a queue of upcoming approvals; each new low-cost pen that reaches pharmacies reinforces (or refutes) the pressure on average ticket sizes.
- Raia Drogasil's Q3 2026 earnings. This earnings report will provide hard figures on how much weight-loss pens contributed to revenue and how margins reacted to the initial rollout of generics.
- The company's strategic response. It is worth observing whether Raia Drogasil positions itself to sell its own generics in volume, transforming part of the threat into a turnover opportunity.
- The evolving revenue share of weight-loss pens. The larger the share this category represented, the greater the impact—and that is the metric the market will reprice with each subsequent financial disclosure.
The selloff on September 24, 2026, did not stem from a company misstep or a bad day on the stock exchange. It resulted from a regulatory regime shift for the most lucrative product on the shelf: expensive drugs turned into low-cost generics. Whether this represents a definitive threat or an overreaction will be answered by upcoming earnings reports and ANVISA's approval pipeline—and that is precisely where shareholders should keep their eyes fixed.
